Literature DB >> 26404080

Oxidovanadium(IV) complexes with chrysin and silibinin: anticancer activity and mechanisms of action in a human colon adenocarcinoma model.

I E León1,2, J F Cadavid-Vargas1,2, I Tiscornia3, V Porro3, S Castelli4, P Katkar4, A Desideri4, M Bollati-Fogolin3, S B Etcheverry5,6.   

Abstract

Vanadium compounds were studied during recent years to be considered as a representative of a new class of nonplatinum metal antitumor agents in combination to its low toxicity. On the other hand, flavonoids are a wide family of polyphenolic compounds synthesized by plants that display many interesting biological effects. Since coordination of ligands to metals can improve the pharmacological properties, we report herein, for the first time, a exhaustive study of the mechanisms of action of two oxidovanadium(IV) complexes with the flavonoids: silibinin Na₂[VO(silibinin)₂2]·6H₂O (VOsil) and chrysin [VO(chrysin)₂EtOH]₂(VOchrys) on human colon adenocarcinoma derived cell line HT-29. The complexes inhibited the cell viability of colon adenocarcinoma cells in a dose dependent manner with a greater potency than that the free ligands and free metal, demonstrating the benefit of complexation. The decrease of the ratio of the amount of reduced glutathione to the amount of oxidized glutathione were involved in the deleterious effects of both complexes. Besides, VOchrys caused cell cycle arrest in G2/M phase while VOsil activated caspase 3 and triggering the cells directly to apoptosis. Moreover, VOsil diminished the NF-kB activation via increasing the sensitivity of cells to apoptosis. On the other hand, VOsil inhibited the topoisomerase IB activity concluding that this is important target involved in the anticancer vanadium effects. As a whole, the results presented herein demonstrate that VOsil has a stronger deleterious action than VOchrys on HT-29 cells, whereby suggesting that Vosil is the potentially best candidate for future use in alternative anti-tumor treatments.

Entities:  

Keywords:  Flavonoids; HT-29 human colon adenocarcinoma cells; Mechanisms of action; Metal based drug; Vanadium

Mesh:

Substances:

Year:  2015        PMID: 26404080     DOI: 10.1007/s00775-015-1298-7

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  72 in total

1.  Vanadium mediated apoptosis and cell cycle arrest in MCF7 cell line.

Authors:  Rajarshi Sankar Ray; Basabi Rana; Biswanath Swami; Venkatappan Venu; Malay Chatterjee
Journal:  Chem Biol Interact       Date:  2006-08-18       Impact factor: 5.192

2.  Vanadium-vitamin B12 bioconjugates as potential therapeutics for treating diabetes.

Authors:  Riya Mukherjee; Edward G Donnay; Michal A Radomski; Catherine Miller; Duane A Redfern; Arne Gericke; Derek S Damron; Nicola E Brasch
Journal:  Chem Commun (Camb)       Date:  2008-06-20       Impact factor: 6.222

Review 3.  Linking inflammation reactions to cancer: novel targets for therapeutic strategies.

Authors:  Alberto Mantovani; Federica Marchesi; Chiara Portal; Paola Allavena; Antonio Sica
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

Review 4.  Vanadium in the detection, prevention and treatment of cancer: the in vivo evidence.

Authors:  Anupam Bishayee; Abhijeet Waghray; Mehool A Patel; Malay Chatterjee
Journal:  Cancer Lett       Date:  2010-03-04       Impact factor: 8.679

5.  Synthesis, characterization, and preliminary in vitro studies of vanadium(IV) complexes with a Schiff base and thiosemicarbazones as mixed-ligands.

Authors:  Nerissa A Lewis; Fange Liu; Luke Seymour; Anthony Magnusen; Travis R Erves; Jessa Faye Arca; Floyd A Beckford; Ramaiyer Venkatraman; Antonio González-Sarrías; Frank R Fronczek; Don G Vanderveer; Navindra P Seeram; Aimin Liu; William L Jarrett; Alvin A Holder
Journal:  Eur J Inorg Chem       Date:  2012-02-01       Impact factor: 2.524

Review 6.  The transcription factor nuclear factor-kappa B and cancer.

Authors:  R O Escárcega; S Fuentes-Alexandro; M García-Carrasco; A Gatica; A Zamora
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-03       Impact factor: 4.126

7.  In vitro study of the insulin-mimetic behaviour of vanadium(IV, V) coordination compounds.

Authors:  Dieter Rehder; João Costa Pessoa; Carlos F G C Geraldes; MargaridaM C A Castro; Themistoklis Kabanos; Tamás Kiss; Beate Meier; Giovanni Micera; Lage Pettersson; Maria Rangel; Athanasios Salifoglou; Iztok Turel; Dongren Wang
Journal:  J Biol Inorg Chem       Date:  2001-12-19       Impact factor: 3.358

8.  Impaired antioxidant status in diabetic rat liver. Effect of vanadate.

Authors:  A K Saxena; P Srivastava; R K Kale; N Z Baquer
Journal:  Biochem Pharmacol       Date:  1993-02-09       Impact factor: 5.858

Review 9.  Vanadium treatment of type 2 diabetes: a view to the future.

Authors:  Katherine H Thompson; Jay Lichter; Carl LeBel; Michael C Scaife; John H McNeill; Chris Orvig
Journal:  J Inorg Biochem       Date:  2008-12-24       Impact factor: 4.155

10.  Effect on DNA relaxation of the single Thr718Ala mutation in human topoisomerase I: a functional and molecular dynamics study.

Authors:  Giovanni Chillemi; Paola Fiorani; Silvia Castelli; Alessandro Bruselles; Piero Benedetti; Alessandro Desideri
Journal:  Nucleic Acids Res       Date:  2005-06-08       Impact factor: 16.971

View more
  16 in total

1.  Toxicity of Nanocomplexes Containing Gadolinium Orthovanadate Nanoparticles and Cholesterol.

Authors:  Anatoliy Goltsev; Natalia Babenko; Yuliia Gaevska; Mykola Bondarovych; Tetiana Dubrava; Lyudmila Ostankova; Nataliia Volkova; Vladimir Klochkov
Journal:  Biol Trace Elem Res       Date:  2022-01-13       Impact factor: 4.081

2.  In vitro and in vivo antitumor effects of the VO-chrysin complex on a new three-dimensional osteosarcoma spheroids model and a xenograft tumor in mice.

Authors:  Ignacio E León; Juan F Cadavid-Vargas; Agustina Resasco; Fabricio Maschi; Miguel A Ayala; Cecilia Carbone; Susana B Etcheverry
Journal:  J Biol Inorg Chem       Date:  2016-10-01       Impact factor: 3.358

3.  Improved chemotherapeutic efficacy of injectable chrysin encapsulated by copolymer nanoparticles.

Authors:  Kyoung Mee Kim; Hyun Kyung Lim; Sang Hee Shim; Joohee Jung
Journal:  Int J Nanomedicine       Date:  2017-03-09

4.  Characterization and cytotoxic effect of aqua-(2,2',2''-nitrilotriacetato)-oxo-vanadium salts on human osteosarcoma cells.

Authors:  Aleksandra Tesmar; Dariusz Wyrzykowski; Rafał Kruszyński; Karolina Niska; Iwona Inkielewicz-Stępniak; Joanna Drzeżdżon; Dagmara Jacewicz; Lech Chmurzyński
Journal:  Biometals       Date:  2017-02-15       Impact factor: 2.949

Review 5.  New Insights toward Colorectal Cancer Chemotherapy Using Natural Bioactive Compounds.

Authors:  Saúl Redondo-Blanco; Javier Fernández; Ignacio Gutiérrez-Del-Río; Claudio J Villar; Felipe Lombó
Journal:  Front Pharmacol       Date:  2017-03-14       Impact factor: 5.810

6.  Activation of Sirtuin 3 by Silybin Attenuates Mitochondrial Dysfunction in Cisplatin-induced Acute Kidney Injury.

Authors:  Yin Li; Zengchun Ye; Weiyan Lai; Jialing Rao; Wanbing Huang; Xiaohao Zhang; Ziying Yao; Tanqi Lou
Journal:  Front Pharmacol       Date:  2017-04-05       Impact factor: 5.810

Review 7.  Silymarin and Cancer: A Dual Strategy in Both in Chemoprevention and Chemosensitivity.

Authors:  Dominique Delmas; Jianbo Xiao; Anne Vejux; Virginie Aires
Journal:  Molecules       Date:  2020-04-25       Impact factor: 4.411

Review 8.  Nanomedicines in the treatment of colon cancer: a focus on metallodrugs.

Authors:  Pedro Farinha; Jacinta O Pinho; Mariana Matias; M Manuela Gaspar
Journal:  Drug Deliv Transl Res       Date:  2021-02-22       Impact factor: 4.617

9.  Inhibitory effects of silibinin on proliferation and lung metastasis of human high metastasis cell line of salivary gland adenoid cystic carcinoma via autophagy induction.

Authors:  Canhua Jiang; Shufang Jin; Zhisheng Jiang; Jie Wang
Journal:  Onco Targets Ther       Date:  2016-10-26       Impact factor: 4.147

Review 10.  Molecular and Cellular Mechanisms of Cytotoxic Activity of Vanadium Compounds against Cancer Cells.

Authors:  Szymon Kowalski; Dariusz Wyrzykowski; Iwona Inkielewicz-Stępniak
Journal:  Molecules       Date:  2020-04-10       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.